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Abstract
Introduction: Gender differences have been recently highlighted for several aspects of acne vulgaris such as
epidemiology, pathogenesis, clinical course, quality of life and treatment outcome. In particular a shorter but more
severe clinical course has been reported in males than in females; nevertheless, usually men have their quality of
life less affected.
Aim: To determine if the response and the adverse events to 1 cycle of oral isotretinoin therapy can be
influenced by gender.
Methods: A retrospective study was conducted on consecutive patients affected by acne vulgaris and treated
with oral isotretinoin. Global acne grading system (GAGS), acne-related quality of life (AQoL) and isotretinoin-related
adverse events were considered as outcome measures and were evaluated before (T0), every month during
administration and 4 weeks after the withdrawal (T1) of oral isotretinoin therapy. Mann-Whitney U test and
Wilcoxon signed-rank test were used for quantitative parameters and Fisher exact test for qualitative ones.
Results: Forty-nine acneic patients were retrospectively selected (33 males 67.3% and 16 females -32.7%;
median age: 19 years). Patients had received a median dosage of isotretinoin of 0.4 mg/kg/die for a median period
of 5 months; no differences in outcome measures among genders were reported.
Limitations: The study is retrospective and the sample is small and not homogenously distributed among
genders, as males are double in number than females.
Conclusions: In our study population gender didn't influence neither the clinical and the quality of life outcome
measures nor the occurrence of adverse events to oral isotretinoin therapy for acne.
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Abbreviations:
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Introduction
Acne (synonym "acne vulgaris") is one of the most frequent skin
diseases. It primary involves adolescents of Western industrialized
countries, with a prevalence between 50% and 95%. It shows a male
predominance and the frequency of moderate and severe forms is
20-35% [1,2].
The pathogenesis involves both innate and adaptive immunity and
4 main factors interact: seborrhoea, pilar infundibular hyper-
keratinization, propionibacterium acnes follicular colonization and
release of inflammatory mediators [3].
Acne is a polymorphic disease and several clinical forms have been
described; however 3 major subtypes could be recognised: comedonal,
papulopustular and nodular/conglobate [4].
The therapeutic armamentarium involves both topical and systemic
treatments. Oral isotretinoin is widely considered as the most effective
treatment option, as it acts against all major pathogenic factors of acne
[5].
In last decades, few studies have suggested that the clinical course
and the therapeutic outcome of acne could be influenced by gender,
although conflicting results have been reported at these purposes [6].
In particular male patients seem to be prone to develop more severe
forms, with a shorter clinical course, than females, [7] while females
usually have their quality of life indexes more affected than males
[8,9].
An expert panel of Canadian dermatologists [10] has recently
recommended that the therapeutic management of acne should be
based not only on clinical severity assessment, as suggested by the
majority of guidelines, [11] but on multiple demographics and psycho-
social aspects, including gender [12]. Furthermore, male gender has
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been associated with the occurrence of more severe flares, during oral
isotretinoin therapy, than females [13,14].
We retrospectively analyzed a 2-year experience with oral
isotretinoin for acne, evaluating clinical and quality of life indexes and
side effects occurrence, in order to assess if gender could influence
these outcome measures.
Methods
Study population
We retrospectively selected consecutive patients affected by acne
vulgaris and treated with oral isotretinoin, who were attending our
outpatient clinic from January 2009 to January 2011.
Demographic data and information about clinical history and oral
isotretinoin therapy were collected from our records, which included:
comorbidities, family history of acne, previous therapies, number of
therapeutic cycles, mean dosage and duration of treatment (expressed
as the duration in months of the first cycle), GAGS (global acne
grading system) and AQoL (acne-related quality of life) values at T0
(baseline) and T1 (4 weeks after the first isotretinoin cycle
withdrawal).
Furthermore database was checked for clinical and laboratory
isotretinoin-related adverse events; the former included: cheilitis,
xerosis, scalp or hand dermatitis, keratitis, myalgia, and epistaxis,
while the latter consisted of: altered blood cell count, high lipid levels,
liver and/or renal dysfunction. All the patients had been monthly
evaluated for such adverse events during the isotretinoin treatment
and at least for 1 month after therapy withdrawal.
Outcome measures
We considered GAGS and AQoL scores and occurrence of clinical
and/or laboratory adverse events as outcome measures. Regarding
adverse events, patients were classified in 2 groups, according to both
the occurrence (presence or absence) and the number (1 or >1) of
adverse events.
Our primary endpoint consisted in the evaluation of gender
influence on outcome measures. For this purpose we compared the
improvement of GAGS and AQoL scores (from T0 to T1) and to the
occurrence of adverse events among genders. As secondary endpoint
we considered the clinical and quality of life improvement (GAGS and
AQoL scores) and the occurrence of adverse event in the entire study
population.
GAGS score is widely used to express clinical severity of acne
vulgaris. It ranges from 0 to 44: for each type of lesion is given a value
depending on severity (no lesions=0, comedones=1, papules=2,
pustules=3 and nodules=4); a local score for different areas (forehead,
right cheek, left cheek, nose, chin, chest and upper back) is calculated
using the formula: Local score=Factor × Grade. A factor of 3 is
assigned to the chest and upper back, a factor of 2 to the forehead and
cheeks and a factor of 1 to the other sides. The global score is the sum
of local scores. A score of 1-18 is considered mild; 19-30, moderate;
31-38, severe; and >39, very severe [15].
AQoL is a 19-item patient reported outcome measure evaluating the
the acne-related quality of life.
The questionnaire consists of 4 domains: self-perception, role-
emotional, acne symptoms and role-social. The first 3 domains are
composed of 5 items each with scores ranging from 0 to 30. The role-
social domain includes 4 items with scores ranging from 0 to 24.
Responses are based on a 7-point adjectival scale; responses of
‘‘extremely’’ to ‘‘not at all’’ are used for 16 of the 19 items and
responses of ‘‘extensive’’ to ‘‘none’’ are used for 3 of the 5 symptom-
related items. The higher the AQoL score, the better the quality of life
[16].
Statistical Analysis
Data are expressed as median values
Mann-Whitney U test and Wilcoxon signed-rank test were used to
compare the quantitative parameters, as the normality test of
Kolmogorov-Smirnov failed (age, months of the first cycle, dosage,
GAGS and AQoL values and GAGS and AQoL % improvement).
Fisher exact test was employed for qualitative variables (family
history of acne vulgaris, occurrence and number of clinical and
laboratory adverse events).
Statistical analysis was performed with IBM SPSS 21.0 package
(Statistical Package for Social Sciences, SPSS Inc., Chicago, Ill.).
Statistical significance was fixed at p<0.05.
Results
We retrospectively selected 49 patients affected by acne and treated
with oral isotretinoin. Thirty-three (67.3%) were males and 16 (32.7%)
were females, with a median age of 19 (16-37) years. Table 1
summarizes demographic features of the study population.
The median age was significantly lower in males than females (18
years vs. 23.5 years, respectively; Mann-Whitney U test, p<0.001).
Almost all the patients received 1 cycle of oral isotretinoin and were
treated for a median period of 5 months with a median dosage of 0.4
mg/kg/die; only 3 (6.1%) female patients received more than 1 cycle (2
received 2 cycles and only 1 received 3 cycles); thus we decided to
consider only the duration of the first cycle for these patients.
No differences were highlighted among genders regarding family
history of acne, isotretinoin doses, duration of the first cycle of therapy
and in GAGS and AQoL scores at T0.
Regarding comorbidities, only 5 females were affected by polycystic
ovarian syndrome (PCOS) and had been previously treated with oral
estroprogestins; another female patient had received doxycycline 100
mg/bid for 3 months. However no concomitant therapies to oral
isotretinoin were reported.
We found a significant improvement of the median values of both
GAGS and AQoL scores after 1 cycle of oral isotretinoin in the entire
study population (from 27 to 5 for GAGS and from 59 to 92 for AQoL;
Wilcoxon signed-rank test p<0.001 for both [data not tabulated]),
however no differences were highlighted among genders both in
median values of GAGS and AQoL at T1 (median GAGS at T1: 5 in
males and 2 in females; median AQoL at T1: 93 in males and 92 in
females; Mann-Whitney U test p=0.876 and p=0.393, respectively) and
in their median percentage of improvement from T0 to T1 (median
GAGS% improvement: 47.7% in males and 51.1% in females; median
AQoL% improvement: 30% in males and 33% in females; Mann-
Whitney U test p=0.492 and p=0.337, respectively) (Table 2).
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Variables Males
33 (67.3%)
Females
16 (32.7%)
Total
49
p value#
Median Age (years) 18 (16-33) 23.5 (17-37) 19 (16-37) <0.001*
Number of cycles 1 (1-1) 1 (1-3) 1 (1-3) 0.011*
Months of the first cycle 5 (1-6) 5 (1-6) 5 (1-6) 0.899*
Dose/kg (mg/kg/die) 0.4 (0.2-0-6) 0.4 (0.3-0.5) 0.4 (0.2-0-6) 0.727*
Familiar history of acne vulgaris No 11 (33.3%) 3 (18.7%) 14 0.336†
Yes 22 (66.7%) 13 (81.3%) 35
Comorbidities No 33 (100%) 11 (68.7%) 44 0.002†
Yes 0 (0%) 5 (31.3%) 5
GAGS T0 25 (20-41) 29 (22-36) 27 (20-41) 0.164*
AQoL T0 61 (8-92) 57 (10-87) 59 (8-92) 0.393*
#p value<0.05; *Mann-Whitney U test for quantitative variables; †Fisher test for qualitative variables; GAGS: Global Acne Grading System; AQoL: Acne Quality of Life.
Table 1: Demographic data and GAGS and AQoL values at T0, expressed per gender.
Variables Males
33 (67.3%)
Females
16 (32.7%)
Total
49
p value#
Number of clinical adverse events 1 28 (84.8%) 10 (71.4%) 38 0.419*
>1 5 (15.2%) 4 (28.6%) 9
Occurrence of clinical adverse events No 0 (0%) 2 (12.5%) 2 0.102†
Yes 33 (100%) 14 (87.5%) 47
Occurrence of laboratory adverse events No 32 (97.0%) 16 (100%) 48 0.673†
Yes 1 (3.0%) 0 (0%) 1
GAGS T1 5 (0-25) 2 (0-25) 5 (0-25) 0.876*
AQoL T1 93 (15-120) 92 (20-120) 92 (15-120) 0.393*
GAGS% improvement 47.7%
(15.9%-93.2%)
51.1%
(9.1%-81.8%)
50.0%
(9.1%-93.2%)
0.429*
AQoL% improvement 30.0%
(7.0%-78.0%)
33.0%
(3.0%-94.0%)
30.0%
(3.0%-94.0%)
0.337*
#p value<0.05; *Mann-Whitney U test for quantitative variables; †Fisher test for qualitative variables; GAGS: Global Acne Grading System; AQoL: Acne Quality of Life.
Table 2: Adverse events and GAGS and AQoL values and percentage of improvement at T1, expressed per gender.
Figures 1 and 2 report the clinical pictures of a male and a female
patient, respectively, before and after 1 cycle of oral isotretinoin
therapy.
All but 2 female patients experienced at least 1 isotretinoin-related
clinical adverse event, however no severe or systemic events were
reported. Only 1 male patient experienced a laboratory adverse event,
namely a transitory mild thrombocytopenia that resolved in 1 week
after isotretinoin withdrawal.
Thirty-seven patients had only 1 clinical adverse event (27
males-73.0% and 10 females-27.0%); the most common were cheilitis
(22 patients-59.5%; 16 males-72.7% vs. 6 females-27.3%) and xerosis
(12 patients-32.4%; 10 males-80.3% vs. 2 females-19.7%), while
epistaxis and scalp dermatitis were reported only in 2 different female
patients (5.4% in total) and myalgia only in 1 male (2.7%).
Nine patients experienced 2 clinical adverse events (5-55.6% males
and 4 females-44.4%) and 1 male patient (2.1%) reported 3 of them
(cheilitis, xerosis and keratitis). The most common association was
between cheilitis and xerosis (6 patients-66.7%; 4 males vs. 2 females);
moreover 1 male (11.1%) had both cheilitis and keratitis and 2 females
(22.2%) had both cheilitis and scalp or hand dermatitis.
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No significant differences were reported among genders regarding
both the occurrence and the number (1 or >1) of clinical and
laboratory adverse events (Table 2).
Figure 1: A 19-year-old male patient: a-c) before and d-f) after a 4
months cycle of oral isotretinoin therapy.
Figure 2: A 26-year-old female patient: a-c) before and d-f) after a 5
months cycle of oral isotretinoin therapy.
Discussion
In this study we didn't find significant differences among genders,
neither in clinical and quality of life outcome measures of isotretinoin
therapy, nor in isotretinoin-related adverse events.
Acne is a common skin condition with substantial cutaneous and
psychological disease burden. [5] Studies suggest that the emotional
impact of acne is comparable to that experienced by patients with
systemic diseases, like diabetes and epilepsy [17]. Most severe forms of
acne vulgaris are usually associated with greater quality of life
impairment [18].
Acne is a multi-factorial inflammatory skin disease involving both
genetic and environmental factors. The latter primarily regard life style
and in particular diet habits [19]. The former have been primarily
suggested by the increased risk of acne in case of a positive family
history [20]. Recently a genome wide association study (GWAS)
identified several chromosomal loci associated with acne vulgaris; [21]
probably also gender and ethnical differences in clinical course and
therapy outcomes of acne could be related to genetic factors.
Oral isotretinoin is considered as the most effective treatment in
severe forms of acne [5,22]. Recently the European evidence-based
guidelines for the treatment of acne stated that systemic isotretinoin
must be considered the first-choice treatment for severe
papulopustular and nodular/conglobate forms of acne because of its
clinical effectiveness, prevention of scarring and quick improvement of
patients’ quality of life. [5] Experience from more than 3 decades has
clearly defined efficacy and safety profiles of this drug [23,24].
Previous studies have only partially clarified the differences between
females and males regarding isotretinoin use [13,14].
We reported no significant gender differences in family history of
acne vulgaris and in doses and duration of isotretinoin therapy
parameters, in our study population; however, only female patients
had comorbidities (PCOS) and underwent previous therapies. Besides,
males resulted significantly younger than females; this is not
surprising, as isotretinoin therapy is usually reserved to the most
severe forms of acne vulgaris that involve more frequently male
patients, younger than females [7].
Furthermore, GAGS and AQoL showed no significant differences
among genders both at T0 and at T1. Contradictory results about the
influence of gender on clinical course and quality of life of acne
vulgaris have been reported in literature. A greater impairment of
clinical scores in males and of quality of life in females has been often
reported [7-9].
Regarding adverse events, we didn't find statistically significant
differences among genders, both regarding their occurrence and
number (1 or >1), even if males are more likely to experience cheilitis
and more than 1 averse event, while females are more affected by
xerosis.
Limitations of this retrospective study are represented by the small
study sample and by the fact that males are double in number than
females.
In conclusion, our study didn’t show significant differences among
genders, neither in clinical and quality of life outcomes of oral
isotretinoin treatment nor in isotretinoin-related adverse events
occurrence. However further prospective studies, with wider patient
samples, are needed to confirm our observations.
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